相关实验视频
Updated: Jan 12, 2026

09:15
In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
1.1K
主要抗凝药用比瓦利鲁丁对抗肝素为微轴流量支持的患者
Mario Gramegna1, Anna Stegmann2,3, Marina Pieri4,5
1From the Cardiothoracic and Vascular Anesthesia and Intensive Care, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
概括
直接血栓抑制剂 (DTIs) 和肝素在微轴流量患者的抗凝治疗中显示出相似的结果. DTI可能提供更稳定的激活的部分血栓塑时间控制,减少变化.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 血液相容性问题在需要微轴流量 (mAFP) 支持的重症患者中很常见.
- 直接血栓抑制剂 (DTIs) 在暂时机械循环支持 (tMCS) 中显示出抗凝作用的希望.
研究的目的:
- 为了比较基于直接血栓激素抑制剂 (DTI) 和基于肝素的抗凝药在心脏性休克 (CS) 患者支持mAFP.
主要方法:
- 从2018年到2023年对180名成年CS患者在mAFP上进行了回顾性分析.
- 患者接受了氨酸或比瓦利鲁丁 (DTI) 作为抗凝药.
- 使用治疗权重的逆概率 (IPWT) 来平衡分析组.
主要成果:
- 27%的患者出现出血,10%的患者出现血栓形成.
- 在IPWT分析中,DTI和肝素组之间的临床结果 (出血,血液溶解) 和存活率相似.
- DTI组表现出较少的激活部分血栓形成时间 (aPTT) 变化和延长的aPTT值 (p < 0.001).
结论:
- 在mAFP患者中,基于DTI的抗凝药是一种可行的黑巴林替代品,具有可比的安全性和有效性.
- 根据aPTT测量,DTI可能会提供更稳定的抗凝血控制.
- 这项研究代表了对mAFP支持的抗凝血策略的最大调查.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
273
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
273
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
298
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
298
Hemodialysis I: Introduction
1.3K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
1.3K

